BiomX Inc. (PHGE): Price and Financial Metrics


BiomX Inc. (PHGE): $0.35

0.01 (+1.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PHGE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PHGE Stock Price Chart Interactive Chart >

Price chart for PHGE

PHGE Price/Volume Stats

Current price $0.35 52-week high $2.14
Prev. close $0.34 52-week low $0.13
Day low $0.33 Volume 145,516
Day high $0.35 Avg. volume 672,861
50-day MA $0.24 Dividend yield N/A
200-day MA $0.60 Market Cap 10.36M

BiomX Inc. (PHGE) Company Bio


BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.


PHGE Latest News Stream


Event/Time News Detail
Loading, please wait...

PHGE Latest Social Stream


Loading social stream, please wait...

View Full PHGE Social Stream

Latest PHGE News From Around the Web

Below are the latest news stories about BIOMX INC that investors may wish to consider to help them evaluate PHGE as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's the final day of trading this week and we're checking in on the biggest pre-market stock movers for Friday morning!

William White on InvestorPlace | January 20, 2023

BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

NESS ZIONA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 1st Annual Investor Conference on

Wallstreet:Online | November 29, 2022

BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update

Continued Progress Enrolling Patients in Phase 1/2 Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis; Results from Part 1 of the Trial Now Expected in Q1 2023

GlobeNewswire | November 9, 2022

BiomX GAAP EPS of -$0.23 in-line

BiomX press release (PHGE): Q3 GAAP EPS of -$0.23 in-line.Cash balance, short-term deposits and restricted cash as of September 30, 2022, were $41.5 million, compared to $63.1 million…

Seeking Alpha | November 9, 2022

BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022

NESS ZIONA, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, November 9, 2022, at 8:00 a.m. ET, to report third quarter 2022 financial results and provide business updates.

GlobeNewswire | November 2, 2022

Read More 'PHGE' Stories Here

PHGE Price Returns

1-mo 84.21%
3-mo -7.21%
6-mo -60.99%
1-year -76.51%
3-year -96.39%
5-year N/A
YTD 87.47%
2022 -88.33%
2021 -74.92%
2020 -34.12%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6355 seconds.